Biofourmis' therapeutic platform is based on emerging clinical evidence that drug-software combinations can enhance clinical effectiveness, including patient reported outcomes. It has the potential of getting the right patients on the right drugs at the right dosage in a timely manner," said Dr. Maulik Majmudar, a cardiologist and member of Biofourmis' Clinical Advisory Board. "Leveraging Biofourmis' platform to support people with complex chronic conditions at scale is an important step in making a meaningful impact on people's quality of life."
About Biofourmis
Biofourmis is a fast-growing global start-up that is on a mission of augmenting personalized care and therapies with Digital Therapeutics for better management of patients with complex chronic conditions. They discover, develop and deliver clinically-validated software-based therapeutics to provide better outcomes for patients, advanced tools for clinicians to deliver personalized care, and cost-effective solutions for payers. Biofourmis has built Biovitals™, a highly sophisticated personalized AI-empowered health analytics platform that predicts clinical exacerbation days in advance before a critical event, which is the backbone of their Digital Therapeutics product pipeline across therapeutic areas including heart failure, acute coronary syndrome, COPD, and chronic pain.
SOURCE Biofourmis
Back to HCB News
